Published in J Clin Pharmacol on February 01, 2012
Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole | NCT00942773
Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy (2014) 0.96
How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care (2014) 0.89
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy (2014) 0.88
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol (2015) 0.85
Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation. Antimicrob Agents Chemother (2013) 0.84
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. Curr Fungal Infect Rep (2015) 0.83
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug Des Devel Ther (2015) 0.81
A retrospective analysis of patient-specific factors on voriconazole clearance. J Pharm Health Care Sci (2016) 0.81
Use of antifungal drugs in hematology. Rev Bras Hematol Hemoter (2012) 0.79
Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype. Pharmacotherapy (2013) 0.78
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. AIDS Res Ther (2014) 0.77
Treatment principles for the management of mold infections. Cold Spring Harb Perspect Med (2014) 0.77
Successful management of voriconazole-associated hyponatremia with therapeutic drug monitoring. Antimicrob Agents Chemother (2013) 0.75
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol (2015) 0.75
PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics (2017) 0.75
Therapeutic drug monitoring in voriconazole-associated hyponatremia. Med Mycol Case Rep (2013) 0.75
Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients. Ther Drug Monit (2017) 0.75
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol (2007) 2.71
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol (2006) 2.69
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ (2006) 2.01
The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis (2012) 1.76
Current status of the institutional review boards in Korea: constitution, operation, and policy for protection of human research participants. J Korean Med Sci (2003) 1.75
A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. Hum Mol Genet (2003) 1.40
Combined use of crushed cartilage and fibrin sealant for radix augmentation in Asian rhinoplasty. Plast Reconstr Surg (2015) 1.38
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther (2005) 1.35
Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol (2008) 1.33
MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics (2007) 1.23
Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics (2011) 1.14
Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther (2012) 1.09
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther (2004) 1.08
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother (2009) 1.04
Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther (2005) 1.04
BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett (2006) 1.02
Estrogen receptor-alpha gene haplotype is associated with primary knee osteoarthritis in Korean population. Arthritis Res Ther (2004) 1.02
A comparison of ketamine and lidocaine spray with propofol for the insertion of laryngeal mask airway in children: a double-blinded randomized trial. Anesth Analg (2002) 1.01
Voriconazole-associated severe hyponatremia. Med Mycol (2011) 1.00
Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos (2004) 0.99
Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol (2004) 0.99
YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res (2006) 0.97
Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics (2009) 0.96
Gastroprotective action of Cochinchina momordica seed extract is mediated by activation of CGRP and inhibition of cPLA(2)/5-LOX pathway. Dig Dis Sci (2009) 0.96
Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.95
Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs (2012) 0.93
Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea. J Gastroenterol Hepatol (2009) 0.93
Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults. Vaccine (2011) 0.93
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model (2007) 0.92
Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol (2013) 0.92
Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res (2009) 0.92
Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney. PLoS One (2012) 0.92
Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos (2010) 0.91
Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice. Hepatology (2011) 0.90
Positive relationship between melatonin receptor type 1B polymorphism and rheumatoid factor in rheumatoid arthritis patients in the Korean population. J Pineal Res (2005) 0.90
A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther (2004) 0.90
Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol (2011) 0.90
Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther (2012) 0.90
Verification of biomarkers for diabetic retinopathy by multiple reaction monitoring. J Proteome Res (2010) 0.88
Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett (2004) 0.88